Skip to main content


  • Poster presentation
  • Open Access

Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen

Retrovirology20052 (Suppl 1) :P61

  • Published:


  • Infectious Disease
  • Cancer Research
  • Didanosine
  • Lymphopenia
  • Cell Depletion

In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.


Authors’ Affiliations

L'Association Soliderite Sainte, Congo, Africa


© The Author(s) 2005